Research Reports | Market Assessment
November 2018

Dyslipidemia | Disease Landscape and Forecast | G7 | 2018

Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease. With respect to lipid-modifying therapies, the greatest commercial success has come via agents reducing low-density lipoprotein (LDL)-cholesterol, but research and development focusing on triglycerides, high-density lipoprotein (HDL)-cholesterol, and other novel biomarkers is ongoing, with the aim of ultimately providing CV benefits. During the 2017-2027 forecast period, the dyslipidemia market is expected to have two distinct phases: 1) early contraction owing largely to the genericization of the dominant statin class, and 2) marked growth due to the emergence of novel therapies, including Amgen’s Repatha, Sanofi/Regeneron Pharmaceuticals’ Praluent, Amarin’s Vascepa, Kowa Pharmaceuticals’ Parmodia (pemafibrate), The Medicines Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, and AstraZeneca’s Epanova.

Questions Answered:

  • What impact will the genericization of AstraZeneca’s Crestor (rosuvastatin)and Merck’s Zetia/Ezetrol (ezetimibe) and Vytorin/Inegy (ezetimibe/simvastatin) have on the dyslipidemia market?
  • How will CV outcomes data for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and omega-3 fatty acid compounds affect the market?
  • How will the anticipated launch of Esperion Therapeutics’ orally administered bempedoic acid affect the use of the injectable PCSK9 inhibitors? Which products will achieve the greatest use and why?
  • What impact will the anticipated launch of Kowa’s Parmodia and AstraZeneca’s Epanova have on the management of hypertriglyceridemia?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports